Lexicon Pharmaceuticals, Inc. LXRX
Set alert
1.44 USD +0.02 +1.41%
At close · Nov 2
1.44 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
1.40 Day range 1.45
1.10 52-week range 2.68
- YTD
- +25.22%
- 1 year
- +4.35%
- Open
- 1.44
- Prev close
- 1.42
- Mkt cap
- 640.74M
- Vol
- 2.02M
- Avg vol
- 2.71M
- EPS
- -0.16
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.40
- High
- 1.45
- Forward P/E
- -11.86
- Beta
- 1.03
- Short ratio
- 11.53
- Inst. own
- 83.69%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 2.33
- 200-d avg
- 1.78
- 1y target
- 3.86
3M chart
Events in this range
- Aug 6, 2026Earnings: -0.06; estimate -0.05023; surprise -19.45%
Signals (13)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 30, 2026 | 3 days ago |
| MACD: Buy Signal | Oct 28, 2026 | 5 days ago |
| RSI: Oversold | Oct 22, 2026 | 1 week ago |
| RSI: Oversold | Oct 16, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 9, 2026 | 3 weeks ago |
| MACD: Sell Signal | Sep 24, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 22, 2026 | 1 month ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| SMA: Bullish | Aug 21, 2026 | 2 months ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 12, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 4, 2026 | 3 months ago |
Key statistics
- Market cap
- 1.01B
- Enterprise value
- 865.33M
- Trailing P/E
- 0.00
- Forward P/E
- -11.86
- PEG ratio
- -13.77
- Price / sales
- 24.25
- Price / book
- 5.77
- EPS (TTM)
- -0.16
- Beta
- 1.03
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -147.38%
- Revenue (TTM)
- 41.47M
- Revenue growth
- -97.60%
- Free cash flow
- -44.77M
- Total cash
- 190.61M
- Total debt
- 59.24M
- Return on equity
- -40.21%
- Shares outstanding
- 444.96M
- Short % of float
- 13.87%
- 50-day average
- 2.33
- 200-day average
- 1.78
Analyst view
Consensus: buy
Buy
Price target (mean) 3.86 +167.8% upside
Now 1.44
- Target (low)
- 2.00
- Target (mean)
- 3.86
- Target (high)
- 6.00
Ratings (0m) 5 3 buy · 2 hold · 0 sell
- Strong buy1
- Buy2
- Hold2
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.0529.
Financials — quick view
LXRX Revenue — quarterly 692.00K
LXRX Net income — quarterly -31.77M
LXRX EPS — quarterly -0.07
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.06 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.05023 | -0.06 | -0.01 | -19.45% |
| May 7, 2026 | Mar 31, 2026 | -0.04 | -0.0026 | +0.04 | +93.50% |
| Mar 5, 2026 | Dec 31, 2025 | -0.07 | -0.04 | +0.03 | +42.86% |
| Nov 6, 2025 | Sep 30, 2025 | -0.07 | -0.04 | +0.03 | +42.86% |
| Aug 6, 2025 | Jun 30, 2025 | -0.08 | 0.01 | +0.09 | +112.50% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 11, 2026 | Citigroup | main | Buy | Buy |
| Mar 23, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 10, 2026 | Citigroup | main | Buy | Buy |
| Mar 5, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 2, 2025 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 7, 2025 | Citigroup | main | Buy | Buy |
About Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- lexpharma.com
News
- Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
- Lexicon Pharmaceuticals Issues Update On Baseline Characteristics Of Patients Randomized Into Its Ongoing Pivotal Phase 3 SONATA-HCM Clinical Trial Evaluating Sotagliflozin In Patients With Symptomatic Hypertrophic Cardiomyopathy; Patient Enrollment Profile Of SONATA-HCM Is Consistent With Study’s Inclusive Design
- Lexicon Highlights Preclinical Studies Showing Biological Effects Of Sotagliflozin In Hypertrophic Cardiomyopathy And Thrombotic Disease Pathways
- Lexicon Pharmaceuticals Q2 2026 Earnings Call: Complete Transcript
- This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
- Cantor Fitzgerald Initiates Coverage On Lexicon Pharmaceuticals with Overweight Rating, Announces Price Target of $8
- Beta Bionics, J.B. Hunt Transport And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
- Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket
- Lexicon Pharmaceuticals Q2 EPS $(0.07) Misses $(0.05) Estimate, Sales $692.000K Miss $3.998M Estimate
- 12 Health Care Stocks Moving In Monday's Intraday Session
Your note
Sign in to keep a note on LXRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AMOUYAL PHILIPPE | Director | Conversion of Exercise of derivative security | Jun 2, 2026 | 374,486 |
| ARTAL PARTICIPATIONS S.A.R.L. | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Apr 29, 2026 | 0 |
| CRUM BRIAN T | General Counsel | Conversion of Exercise of derivative security | Feb 26, 2026 | 428,802 |
| DEBBANE RAYMOND | Director | Conversion of Exercise of derivative security | Jun 2, 2026 | 51,750,200 |
| EXTON MICHAEL | Chief Executive Officer | Conversion of Exercise of derivative security | Feb 26, 2026 | 298,432 |
| GRANOWITZ CRAIG B. M.D., PH.D. | Officer | Conversion of Exercise of derivative security | Feb 26, 2026 | 323,430 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Artal Group S.A. | 39.36% | 175,156,062 | 395.85M | Jun 29, 2026 |
| FMR, LLC | 11.64% | 51,782,045 | 117.03M | Jun 29, 2026 |
| Siren, L.L.C. | 9.96% | 44,303,518 | 100.13M | Jun 29, 2026 |
| Sessa Capital IM, L.P. | 4.26% | 18,960,836 | 42.85M | Jun 29, 2026 |
| Blackrock Inc. | 3.90% | 17,348,741 | 39.21M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 2.23% | 9,901,208 | 22.38M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 3.88% | 17,247,637 | 38.98M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.54% | 6,847,451 | 15.48M | Mar 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.40% | 6,209,944 | 14.03M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 1.14% | 5,083,069 | 11.49M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 0.93% | 4,127,293 | 9.33M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.61% | 2,701,371 | 6.11M | Jun 29, 2026 |